MetrioPharm secures FDA Orphan Drug Designation for Duchenne muscular dystrophy treatment
DMD is the most common form of muscular dystrophy and is a genetic disorder characterised by progressive muscle…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 May 23
DMD is the most common form of muscular dystrophy and is a genetic disorder characterised by progressive muscle…
31 May 23
This strategic acquisition allows Anatomy IT to expand its presence in the ambulatory healthcare sector and bring its…
31 May 23
Application based on results from the registrational TRIDENT-1 trial, in which repotrectinib demonstrated high response rates and durable…
31 May 23
FDA is proposing to require a new type of Medication Guide called Patient Medication Information for prescription drugs…
31 May 23
MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis…
30 May 23
The approval follows the clearance from China’s National Medical Products Administration in April 2023 for the clinical trial…
30 May 23
The Phageriarus development project aims to acquire bacteriophage-derived proteins that can act as Immune Regulators and use them…
30 May 23
EffRx Pharmaceuticals develops and commercialise prescription drugs that target musculoskeletal and rare pathologies on European and global markets…
30 May 23
The non-dilutive financing builds upon the award-winning €30 million seed financing raised in 2022 and demonstrates great confidence…
29 May 23
The MHLW approval was based on the positive findings from the global multicentre CHAMPION-NMOSD phase 3 trial in…